| Company Name: | Elan Corporation PLC | | Ticker Symbol: | ELN | | | WWW Address: | www.elan.com | | CEO: | G. Kelly Martin | | No. of Employees: | 1,687 | | Common Issue Type: | AD | | Business Description: | A neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain.
|
| | | Industry Information: | DRUGS - Drug Delivery [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 6.32 |  -0.03 | 6.21 | 6.56 | 6.35 | 6.47 | 6.31 | 2038474 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,979.2 | 471.4 | 0.80 | -0.15 | 0.00 | 57.5 | 0.0 | 9.13 - 4.61 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 6.32 | $ | | PE Ratio - LTM | 57.5 | |
| Market Capitalisation | 2,979.3 | mil |
| Latest Shares Outstanding | 471.4 | mil |
| Earnings pS (EPS) | -0.15 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 592,887 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 929 | mil |
| Domestic Sales | 72 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 31.00 | % |
| Gross Profit Margin | 54.9 | % |
| EBITDA Margin | -3.5 | % |
| Pre-Tax Profit Margin | -26.8 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | -5.0 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -6.1 | % |
| Current Ratio | 2.0 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 127.0 | % |
| Working Capital pS | 0.67 | $ |
| Cash pS | 0.46 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -1.93 | $ |
| Cash Flow pS | -0.10 | $ |
| Free Cash Flow pS | -0.77 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -3.27 | |
| Price/Cash Flow | -65.6 | |
| Price/Free Cash Flow | -8.2 | |
| P/E as % of Industry Group | 256.0 | % |
| P/E as % of Sector Segment | 241.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -2.2 | 97 | 27,157 | 46,769 |
| 4 Weeks | 6.70 | 5.37 | 5.45 | 16.0 | 109 | 49,467 | 840,942 |
| 13 Weeks | 7.88 | 4.61 | 7.42 | -14.8 | 79 | 46,304 | 2,824,563 |
| 26 Weeks | 8.59 | 4.61 | 6.98 | -9.5 | 75 | 45,007 | 5,625,918 |
| 52 Weeks | 9.13 | 4.61 | 6.27 | 0.8 | 82 | 38,145 | 9,498,135 |
| YTD | 9.13 | 4.61 | - | 5.3 | 86 | 39,714 | 9,015,038 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 6.49 | 6.48 | 6.48 | 7.06 | 6.76 | 0.80 | 0.84 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 19.12 | 91.9 | 24.28 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 3.61 | NA | 13.34 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 11.3 | 6.3 | 31.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.26 | 0.29 | 0.71 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 25.79 |
| Current Ratio | 2.7 |
| Quick Ratio (Acid Test) | 2.1 |
| Liquidity Ratio (Cash) | 1.52 |
| Receivables Turnover | 6.0 |
| Average Collection Period | 60 |
| Working Capital/Equity | -207.5 |
| Working Capital pS | 1.02 |
| Cash-Flow pS | 0.01 |
| Free Cash-Flow pS | -0.70 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.34 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 112.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 118.7 |
| LT Debt/Total Liabilities | 84.1 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 9.02 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 36.24 |
| Tobin's Q Ratio | 1.60 |
| Current P/E Ratio - LTM | 57.50 |
| Enterprise Value (EV)/EBITDA | -136.46 |
| Enterprise Value (EV)/Free Cash Flow | -10.76 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -3.27 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -65.6 |
| Price/Free Cash Flow Ratio - LTM | -8.2 |
| Price/Sales Ratio | 2.75 |
| P/E Ratio (1 month ago) - LTM | 48.3 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 256.0 |
| P/E as % of Sector Segment | 241.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 3.74 |
| Current Liabilities pS | 0.59 |
| Tangible Book Value pS - LTM | -1.93 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 3.25 |
| Cash pS - LTM | 0.46 |
| Cash Flow pS - LTM | -0.10 |
| Free Cash Flow pS - LTM | -0.77 |
| Earnings pS (EPS) | -0.15 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -33.01 |
| Free Cash Flow Margin 5YEAR AVG | -49.92 |
| Net Profit Margin | -7.1 |
| Net Profit Margin - 5YEAR AVRG. | -46.2 |
| Equity Productivity | -4.31 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.65 |
| Return on Capital Invested (ROCI) | -4.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -16.2 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | -3.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -13.0 |
| Gross Profit Margin | 54.9 |
| Gross Profit Margin - 5YEAR AVRG. | 70.5 |
| EBITDA Margin - LTM | -3.5 |
| EBIT Margin - LTM | -13.2 |
| Pre-Tax Profit Margin | -29.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -53.7 |
| Effective Tax Rate | 76.1 |
| Effective Tax Rate - 5YEAR AVRG. | 15.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 100 |
| Revenue per Employee | 592,887 |
| Net Income per Employee | -42,087 |
| Average Collection Period | 71 |
| Receivables Turnover | 6.0 |
| Day's Inventory Turnover Ratio | 29 |
| Inventory Turnover | 12.6 |
| Inventory/Sales | 3.0 |
| Accounts Payble/Sales | 3.77 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 2.08 |
| Fixed Assets Turnover | 0.90 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 2.67 |
| Revenue per $ Plant | 2.84 |
| Revenue per $ Common Equity | -4.31 |
| Revenue per $ Capital Invested | 0.65 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 29.3 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 51.5 |
| Research & Devlopment (R&D) as % of Revenue | 32.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 32.3 |
|
|  
| | |  |  | |
| |